Please use this identifier to cite or link to this item: https://doi.org/10.1124/mol.110.065839
Title: Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib
Authors: Teng, W.C.
Oh, J.W.
New, L.S. 
Wahlin, M.D.
Nelson, S.D.
Ho, H.K. 
Chan, E.C.Y. 
Issue Date: Oct-2010
Citation: Teng, W.C., Oh, J.W., New, L.S., Wahlin, M.D., Nelson, S.D., Ho, H.K., Chan, E.C.Y. (2010-10). Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Molecular Pharmacology 78 (4) : 693-703. ScholarBank@NUS Repository. https://doi.org/10.1124/mol.110.065839
Abstract: Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase inhibitor (ErbB-1 and ErbB-2) used in the treatment of metastatic breast cancer, have been reported. We investigated the inhibition of CYP3A4 by lapatinib as a possible cause of its idiosyncratic toxicity. Inhibition of CYP3A4 was time-, concentration-, and NADPH-dependent, with kinact = 0.0202 min-1 and Ki = 1.709 μM. The partition ratio was approximately 50.9. Addition of GSH did not affect the rate of inactivation. Testosterone protected CYP3A4 from inactivation by lapatinib. The characteristic Soret peak associated with a metabolite-intermediate complex was not observed for lapatinib during spectral difference scanning. However, reduced carbon monoxide (CO)-difference spectroscopy did reveal a 43% loss of the spectrally detectable CYP3A4-CO complex in the presence of lapatinib. Incubation of either lapatinib or its dealkylated metabolite with human liver microsomes in the presence of GSH resulted in the formation of a reactive metabolite (RM)-GSH adduct derived from the O-dealkylated metabolite of lapatinib. In addition, coincubation of lapatinib with ketoconazole inhibited the formation of the RM-GSH adduct. In conclusion, we demonstrated for the first time that lapatinib is a mechanism-based inactivator of CYP3A4, most likely via the formation and further oxidation of its O-dealkylated metabolite to a quinoneimine that covalently modifies the CYP3A4 apoprotein and/or heme moiety. Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics.
Source Title: Molecular Pharmacology
URI: http://scholarbank.nus.edu.sg/handle/10635/106127
ISSN: 0026895X
DOI: 10.1124/mol.110.065839
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

59
checked on Aug 10, 2018

WEB OF SCIENCETM
Citations

52
checked on Jul 9, 2018

Page view(s)

46
checked on Jul 27, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.